Published in Clin Pharmacol Ther on July 25, 2007
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis (2010) 1.83
Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med (2009) 1.77
Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol (2008) 1.70
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost (2008) 1.51
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther (2012) 1.31
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Drug induced interstitial lung disease. Open Respir Med J (2012) 1.12
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
The transcriptional regulation of the human CYP2C genes. Curr Drug Metab (2009) 1.07
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc (2009) 1.07
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009) 1.02
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther (2014) 0.95
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta (2010) 0.93
Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med (2009) 0.90
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother (2008) 0.88
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88
Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J Pediatr Pharmacol Ther (2013) 0.87
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother (2012) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study. Am J Kidney Dis (2012) 0.87
Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One (2014) 0.86
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenet Genomics (2013) 0.85
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol (2008) 0.82
Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Front Pharmacol (2012) 0.81
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis (2009) 0.81
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol (2009) 0.81
Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis (2014) 0.80
Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. Eur J Clin Pharmacol (2011) 0.80
CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol (2007) 0.80
CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol (2012) 0.80
Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.80
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J (2014) 0.79
Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications. Pharmacotherapy (2014) 0.78
Stem cells in pediatric cardiology. Eur J Pediatr (2013) 0.78
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78
Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. Eur J Clin Pharmacol (2010) 0.77
Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med (2008) 0.77
CYP4F2 polymorphism as a genetic risk factor for major hemorrhagic complications in Chinese patients on warfarin therapy. J Geriatr Cardiol (2012) 0.77
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiol Drug Saf (2015) 0.77
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics (2015) 0.76
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol (2012) 0.76
A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy. Blood Cells Mol Dis (2008) 0.76
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J (2010) 0.75
Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. Am J Cardiol (2016) 0.75
Cardiovascular drugs and the genetic response. Methodist Debakey Cardiovasc J (2014) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med (2017) 0.75
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol (2013) 0.75
Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. BMC Genet (2016) 0.75
Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. Med Sci Monit (2015) 0.75
Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study. J Law Med Ethics (2016) 0.75
A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese. Springerplus (2014) 0.75
Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. Meta Gene (2016) 0.75
Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population. J Pharmacol Pharmacother (2013) 0.75
Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease? Wien Klin Wochenschr (2009) 0.75
Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics (1992) 21.26
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev (2002) 6.00
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med (1993) 4.03
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke (2006) 3.49
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02
Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev (2002) 2.99
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 2.83
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost (2006) 2.22
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med (2005) 2.06
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther (2007) 2.01
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev (2002) 1.86
Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy (2004) 1.82
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 1.73
Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67
Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.64
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther (2004) 1.60
Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 1.47
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther (2005) 1.35
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol (2005) 1.31
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost (2005) 1.23
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.20
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med (2005) 1.20
Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care (2004) 1.17
Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica (2002) 1.14
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med (2003) 1.10
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther (2006) 1.08
CYP2C9*3 allelic variant and bleeding complications. Lancet (1999) 1.01
Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy (2005) 0.95
Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther (2004) 0.92
Influence of physical activity on warfarin therapy. Thromb Haemost (1998) 0.90
Search for predictors of nontherapeutic INR results with warfarin therapy. Ann Pharmacother (2005) 0.83
Visual processing impairment and risk of motor vehicle crash among older adults. JAMA (1998) 4.49
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Arterial stiffness and the development of hypertension. The ARIC study. Hypertension (1999) 3.18
Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation (2001) 3.08
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02
Global distribution of Pu isotopes and 237Np. Sci Total Environ (1999) 2.79
Genetic analysis of IDDM: the GAW5 multiplex family dataset. Genet Epidemiol (1989) 2.73
Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum (2001) 2.68
NHLBI family blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann Epidemiol (2000) 2.28
Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst (1997) 2.21
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum (2001) 2.13
Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med (1998) 2.12
Biopsy-induced tricuspid regurgitation after cardiac transplantation. Ann Thorac Surg (1994) 2.07
Vision impairment, eye disease, and injurious motor vehicle crashes in the elderly. Ophthalmic Epidemiol (1998) 2.07
Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke (2000) 2.05
Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus (2002) 2.03
Delayed hospital arrival for acute stroke: the Minnesota Stroke Survey. Ann Intern Med (1998) 1.95
Vision impairment and driving. Surv Ophthalmol (1999) 1.95
Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sports Exerc (1997) 1.94
Estimation of the amount and tissue distribution of rat Thy-1.1 antigen. Eur J Immunol (1974) 1.88
Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem (1993) 1.86
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus (2002) 1.85
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 1.83
Guidelines for credentialing and granting privileges for endoscopic ultrasound. Gastrointest Endosc (2001) 1.81
Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest (1993) 1.79
Visual and medical risk factors for motor vehicle collision involvement among older drivers. Br J Ophthalmol (2008) 1.79
Variations among sublines of inbred AKR mice. Nat New Biol (1973) 1.78
Influence of leisure time physical activity and television watching on atherosclerosis risk factors in the NHLBI Family Heart Study. Atherosclerosis (2000) 1.70
Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation (2001) 1.69
Twelve-year trends in cardiovascular disease risk factors in the Minnesota Heart Survey. Are socioeconomic differences widening? Arch Intern Med (1997) 1.68
Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet (2000) 1.68
Factors related to driving difficulty and habits in older drivers. Accid Anal Prev (2001) 1.67
Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol (2001) 1.62
Aging and dark adaptation. Vision Res (1999) 1.62
Surgical management of temporomandibular joint ankylosis in the pediatric population. Plast Reconstr Surg (1993) 1.60
HMO membership and patient age and the use of specialty care for hospitalized patients with acute stroke: The Minnesota Stroke Survey. Med Care (1999) 1.55
Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics (1975) 1.55
Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol (2000) 1.54
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics (2001) 1.53
An induced bactericidin in the spiny lobster, Panulirus argus. Proc Soc Exp Biol Med (1968) 1.50
Physical activity and incident hypertension in black and white adults: the Atherosclerosis Risk in Communities Study. Prev Med (1999) 1.49
Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study. Am J Hypertens (2000) 1.48
Health-related quality of life and visual and cognitive impairment among nursing-home residents. Br J Ophthalmol (2008) 1.47
Skip patterns in DINAMAP-measured blood pressure in 3 epidemiological studies. Hypertension (2000) 1.47
Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis (2006) 1.47
Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother (1988) 1.46
Elevations of CK-MB following pulmonary embolism. A manifestation of occult right ventricular infarction. Chest (1992) 1.44
Whole-exome sequencing and an iPSC-derived cardiomyocyte model provides a powerful platform for gene discovery in left ventricular hypertrophy. Front Genet (2012) 1.40
Paired-data analysis is required in the study by May et al. Endoscopy (2012) 1.39
Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation. Cathet Cardiovasc Diagn (1995) 1.39
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther (2007) 1.39
Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) (2003) 1.36
Timed instrumental activities of daily living tasks: relationship to visual function in older adults. Optom Vis Sci (2001) 1.35
Isolation and partial characterization of the human homologue of Thy-1. J Exp Med (1980) 1.34
Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens (1997) 1.34
Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol (1999) 1.31
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther (1995) 1.31
A genome scan for renal function among hypertensives: the HyperGEN study. Am J Hum Genet (2000) 1.31
Trypanosoma brucei guide RNA poly(U) tail formation is stabilized by cognate mRNA. Mol Cell Biol (2000) 1.31
Plasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol (1999) 1.31
Aortic root dilatation at sinuses of valsalva and aortic regurgitation in hypertensive and normotensive subjects: The Hypertension Genetic Epidemiology Network Study . Hypertension (2001) 1.29
Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch Biochem Biophys (1998) 1.28
Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos (2001) 1.27
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther (2001) 1.26
Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood (2001) 1.23
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol (1999) 1.23
Exploratory study of incident vehicle crashes among older drivers. J Gerontol A Biol Sci Med Sci (2000) 1.23
Seronegative rheumatoid arthritis. A distinct immunogenetic disease? Arthritis Rheum (1982) 1.22
Effect of Box-Cox transformation on power of Haseman-Elston and maximum-likelihood variance components tests to detect quantitative trait Loci. Hum Hered (2003) 1.22
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther (1997) 1.22
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol (2001) 1.20
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis (2006) 1.20
Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) (2003) 1.19
Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet (2000) 1.19
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics (1997) 1.18
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry (1991) 1.18
Separation of pure polychlorinated biphenyl isomers into two types of inducers on the basis of induction of cytochrome P-450 or P-448. Chem Biol Interact (1977) 1.16
Genetic associations of LYN with systemic lupus erythematosus. Genes Immun (2009) 1.15
Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr (1994) 1.15
One-stage anterior cervical decompression and posterior stabilization. A study of one hundred patients with a minimum of two years of follow-up. J Bone Joint Surg Am (1995) 1.14
Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol (1998) 1.13
Bacteriophage clearance in the oyster (Crassotrea virginica). J Bacteriol (1968) 1.13
Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet (2000) 1.13
Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther (1995) 1.13
Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol (2011) 1.12
Cochlear gene delivery through an intact round window membrane in mouse. Hum Gene Ther (2001) 1.12
Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement. Lupus (2006) 1.12
Is there an association between pre-existing sleep apnoea and the development of glaucoma? Br J Ophthalmol (2006) 1.11
Evidence for multiple determinants of the body mass index: the National Heart, Lung, and Blood Institute Family Heart Study. Obes Res (1998) 1.11
Isolation and characterizaiton of murine cell surface components. I. Purification of milligram quantities of Thy-1.1. J Exp Med (1977) 1.11
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry (2001) 1.11
Splicing defects in the COL3A1 gene: marked preference for 5' (donor) spice-site mutations in patients with exon-skipping mutations and Ehlers-Danlos syndrome type IV. Am J Hum Genet (1997) 1.10
Testing the robustness of the new Haseman-Elston quantitative-trait loci-mapping procedure. Am J Hum Genet (2000) 1.09
Toothpick impaction with localized sigmoid perforation: successful colonoscopic management. Gastrointest Endosc (1999) 1.09
Fusion of liposomes containing a novel cationic lipid, N-[2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium: induction by multivalent anions and asymmetric fusion with acidic phospholipid vesicles. Biochemistry (1989) 1.09